CVAC: CureVac Pharma Market Cap to Revenue

Symbol and logo of brand CureVac Pharma (CVAC)

CureVac N.V. (CVAC) is developing an advanced mRNA vaccine architecture for the rapid suppression of pandemics, yet long-term success depends on the scalability of high-margin production. Reviewing the P/S multiple changes on GURU.Markets, we see that the indicator stands at 12.80, reflecting a balance between innovation and a conservative approach to bio-waste utilization.

Price-to-Revenue Ratio: curevac.com (CVAC) for 07/04/2022 - 01/17/2026

CureVac Corp (CVAC) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Chart curevac.com|CVAC - Analyst Consensus Forecast
- market capitalization information:
Market Valuation CureVac Corp|CVAC - Real Price to Acquire Entire Company
- book value of equity indicators:
Book Value per Share CureVac|CVAC - Company Book Value|Market Value to Book Value curevac.com|CVAC - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital CureVac N.V.|CVAC - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity CureVac Pharma|CVAC - Company Aggregate Debts|Debts to Book Capitalization CureVac Corp|CVAC - Company Long-Term Debts|Company Current Liabilities CureVac|Intermediate Coverage Ratio curevac.com
- company profitability and valuation multiples indicators:
CVAC - Company Net Income|Net Profit Forecast CureVac N.V.|CVAC - Price to Earnings Ratio|Market Cap to Projected Earnings CureVac NV|CVAC - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CureVac Corp|CVAC - Operating profit before deduction of amortization|Net earnings per share for the last four quarters CureVac|CVAC - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months curevac.com|CVAC - Net earnings per share growth this year|Net earnings per share growth forecast for next year CureVac N.V.
- total revenue and sales volume data:
CVAC - Revenue and Sales Volume|Projected Sales Volume curevac.com|CVAC - P/S Multiple|Forward Price-to-Revenue Multiple CureVac Corp
General company analysis:CVAC curevac.com
Mass-produced product of CureVac Pharma

The P/S ratio determines the market value of a business relative to its annual revenue, allowing for an assessment of asset monetization efficiency regardless of current profitability. By analyzing the revenue-based valuation of CureVac N.V. (CVAC), an investor can track the stability of CureVac N.V. (CVAC) during its period of organic growth and the integration of licensing agreements with a pharma behemoth, when traditional profit metrics temporarily lose their relevance.

Competing companies

Price-to-Revenue Coefficient gilead.com|P/S Multiple CDTX (Cidara Therapeutics Inc)|NVAX - Market Cap to Revenue|VALN: Market Cap to Revenue|VIR - P/S Multiple|SIGA Technologies, Inc. (SIGA) - Price-to-Revenue Ratio|emergentbiosolutions.com - Market Capitalization-to-Revenue Ratio|AVIR (Atea Pharmaceuticals, Inc.) - P/S Multiple|Price to Sales Invivyd Corp IVVD|Market Cap to Revenue ENTA (Enanta)|Price-to-Revenue Ratio INO (Inovio Pharma)|P/S Multiple HLVX (HilleVax, Inc.)|P/S Multiple kalaristx.com KLRS|Dyadic - P/S Multiple|NanoViricides, Inc. (NNVC) - Market Cap to Revenue|TLPH (Talphera Corp) - Market Cap to Revenue|Cocrystal Pharma Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Traws Pharma Inc|Market Cap to Revenue Ratio DWTX (Virios Therapeutics)|Market Cap to Revenue QLGN (Qualigen Therapeutics, Inc.)|Price-to-Revenue Coefficient allovir.com|VBI Vaccines - Market Cap to Revenue|Virios Therapeutics Inc. - Price-to-Revenue Ratio|VXRT: Market Cap to Revenue